Neoadjuvant chemotherapy for advanced gastric cancer.
Tran Thi Ngoc Mai MD., Tran Vinh Tho MD.
Department of Chemotherapy, University Medical Center, Ho Chi Minh city, Vietnam
Gastric cancer is one of the top 5 cancers in the world. The cornerstone for treatment of gastric cancer is surgical resection with lymph node dissection. Despite of the development of surgical techinque, the rate of locoregional and distant replapse is still high, even after complete resection. This makes adjuvant therapy mandatory for patients with stomach cancer. The adjuvant treatment recommendation is generally chemoradiotherapy in the United States, perioperative chemotherapy in the United Kingdom, and chemotherapy in Asia. At the UMC, we do gastrectomy with D2 lymph node dissection, and use adjuvant chemotherapy after surgery with Capecitabine-Oxaliplatin. We conducted a retrospective study about survival after gastrectomy and chemotherapy for stage II – III gastric cancer, and gained a comparable results. In this conference, we will share about our experiences in adjuvant chemotherapy for gastric cancer, and make some discussion about other choices in gastric cancer treatment.